<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Allergy, Asthma and Immunology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>14</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>20</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Constructing Chimeric Antigen for Precise Screening of HTLV-I Infection</title>
    <FirstPage>427</FirstPage>
    <LastPage>436</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Hafez</FirstName>
        <LastName>Heydari-Zarnagh</LastName>
        <affiliation locale="en_US">Department of Clinical Biochemistry, Faculty of Medicine, Sabzevar University of Medical Science, Sabzevar, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Kazem</FirstName>
        <LastName>Hassanpour</LastName>
        <affiliation locale="en_US">Department of Pediatrics, Faculty of Medicine, Sabzevar University of Medical Science, Sabzevar, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad Javad</FirstName>
        <LastName>Rasaee</LastName>
        <affiliation locale="en_US">Department of Biotechnology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>19</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>19</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Individual preparation of two human T-cell lymphotropic virus type I (HTLV-I) diagnostic GST fused peptides (MTA-1 and GD21) is time-consuming and expensive. The aim of this study was to design a novel single chimeric antigen (SCA) to obviate separate expression of proteins and reduce the cost of reagent preparation.Structural protein fragments, including immunodominant B cell linear epitopes, were selected and different SCAs were designed. Tertiary structure, epitope exposure, solubility and stability were calculated for each SCA and compared with each other. The synthetic DNA&#xA0; encoding&#xA0; the&#xA0; interested&#xA0; SCA&#xA0; was&#xA0; sub-cloned&#xA0; into&#xA0; pET32a&#xA0; expression&#xA0; vector, expressed as a soluble form in Escherichia coli BL21 (DE3) cells and purified under native condition using affinity chromatography.The SDS-PAGE results indicated that thioredoxin-fused SCA was successfully expressed as a soluble form in E. coli BL21 (DE3) cells. The results of ELISA confirmed that SCA reacted with anti-HTLV-I antibodies in a concentration-dependent manner.Our results indicated that the designed SCA may be a good candidate for the screening of HTLV-I carriers with antigen&#x2013;antibody-based tests.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/590</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/590/525</pdf_url>
  </Article>
</Articles>
